Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0012739 (
disseminated intravascular coagulation
)
8,673
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effect of seven different anabolic steroids (Ethyloestrenol, Methenolone acetate, Norethandrolone, Methylandrostenediol, Oxymetholone, Methandienone, and Stanozolol) on three alpha-globulin antiprotease inhibitors of thrombin and
plasmin
was studied in men with ischaemic heart disease. In distinct contrast to the oral contraceptives, five of the six 17-alpha-alkylated anabolic steroids studied produced increased plasma Antithrombin III levels and five produced decreased levels of plasma alpha2-macroglobulin. The effect on plasma alpha1-antitrypsin levels was less clear-cut but three of the steroids examined produced significantly elevated levels. The increased plasma fibrinolytic activity which the 17-alpha-alkylated anabolic steroids induce is therefore unlikely to be secondary to
disseminated intravascular coagulation
.
...
PMID:Effect of anabolic steroids on plasma antithrombin III. alpha2 macroglobulin and alpha1 antitrypsin levels. 5 96
"Hemorrhage in the newborn" has long been recognized as merely a result of vitamin K deficiency. However, it is also recognized that fibrinolysis, especially the correlation between the plasminogen-activator and
plasmin
-inhibitors, play an important role in this disease during the neonatal period. With this in mind, we compared thromboelastograms (TEG) from samples with and without urokinase (plasminogen-activator). In 13 out of 15 newborn infant blood-samples (prior to and after addition of urokinase) the thromboelastogram showed the pattern of a
consumption coagulopathy
. The change in the concentration of
plasmin
-inhibitor during the neonatal period was also measured using alpha2-macroglobulin, alpha1-antitrypsin and antithrombin III with M-partigen-plates. The value of alpha2-macroglobulin showed normal adult levels but the value of alpha1-antitrypsin and antithrombin III did not even reach half of the adult level. During the newborn period, the
plasmin
-inhibitor shows a remarkable lowering tendency and it may be surmised that with such a lowering tendency
plasmin
-inhibitor may constitute an exceptionally large handicap when the activator is working. This is especially true in the case of lung hemorrhage since the activator arises from a severe pathological state in the lungs and in addition because this is complicated by the lowering of
plasmin
-inhibitor. These results indicate that the low level of
plasmin
-inhibitors work synergistically with the high value of activator. The low level of antithrombin III could be the reason for coagulation disorders such as
disseminated intravascular coagulation
, (DIC).
...
PMID:New neonatal problems of blood coagulation and fibrinolysis. I. The change of plasmin inhibitor levels in the newborn infant. 6 4
Human plasma alpha2-
plasmin
inhibitor in fibrinolytic states was studied using immunochemical methods and radioiodinated plasminogen. The concentration and activity of plasma alpha2-
plasmin
inhibitor decreased when urokinase was added to plasma in vitro or infused intravenously in man. The decrease was associated with the appearance of
plasmin
-alpha2-
plasmin
inhibitor complex which subsequently disappeared from the circulation in a short time. A decrease of other major inhibitors, such as alpha2-macroglobulin and alpha1-antitrypsin, was not observed when the amount of urokinase added or infused was relatively small, and conversion of plasminogen to
plasmin
was not extensive. The formation of
plasmin
-alpha2-macroglobulin complex was observed only when plasma plasminogen was activated with a larger amount of urokinase, and after most of the alpha2-
plasmin
inhibitor was consumed by forming complexes with
plasmin
. The formation of
plasmin
-alpha1-antitrypsin complex was not observed even in the highly activated plasma unless exogenous
plasmin
was added to the plasma. alpha2-Plasmin inhibitor was the only inhibitor of which the concentration in plasma was significantly decreased in patients with
disseminated intravascular coagulation
and fibrinolysis among the major
plasmin
inhibitors in plasma. The most reactive inhibitor for regulating plasma fibrinolysis very likely is alpha2-
plasmin
inhibitor.
...
PMID:The behavior of alpha2-plasmin inhibitor in fibrinolytic states. 6 62
The relationship between factor VIII (AHF) procoagulant activity and factor VIII-related antigen were examined in patients with
disseminated intravascular coagulation
(
DIC
), pulmonary embolism (PE), and coronary artery disease with or without myocardial infarction (MI). It was found that 13 of 13 patients with
DIC
, 17 of 17 patients with PE, and 10 of 12 patients with MI possessed a significantly elevated factor VIII-related antigen to factor VIII activity ratio (VIII-ratio). The VIII-ratio returned to normal in each of 2 patients with
DIC
and 1 paitent with PE after treatment with heparin, heparin and alpha-amino-caproic acid, and heparin and coumadin respectively. In contrast, the VIII-ratio was slightly elevated only in 1 of 15 patients with coronary artery insufficiency without MI. In in vitro studies, after treatment of plasma with thrombin or
plasmin
, factor VIII activity was lost, whereas the amount of factor VIII-related antigen remained the same or was even increased when measured by agarose quantitative immunoelectrophoresis. These observations have led us to conclude that an elevated VIII-ratio is a very sensitive indicator of intravascular coagulation.
...
PMID:In vivo and in vitro effects of thrombin and plasmin on human factor VIII (AHF). 13 71
Fibrinogen was depleted in dogs injected with a single dose of bothropase even if pretreatment followed by a continuous infusion of antifibrinolytic drugs was performed during
defibrination
. The activation of the fibrinolytic system as a secondary effect of the
defibrination
syndrome induced by bothropase injection was blocked completely by aprotinin (Trasylol) but not by EACA. Plasmin activity in spite of the inhibition of plasminogen activator suggests that, either an excess of activator is released in circulation or a
plasmin
-antiplasmin complex is dissociated by the circulating fibrin, according to the hypothesis of Ambrus and Markus [1], and Back et al. [4] for the mechanism of fibrinolysis in vivo. An experimental model is suggested for the study of the fibrinolytic mechanism in vivo, by the association of defibrinating agents, antivenom and antifibrinolytic drugs.
...
PMID:Experimental defibrination and bothropase: a study on the fibrinolytic mechanism in vivo. 14 12
Changes of prekallikrein in the cases with
DIC
were investigated, i.e.,
DIC
cases including disseminated metastasis of gastric cancer, acute promyelocytic leukemia and endotoxin shock. Therefore, the trigger substances for this paper were the pathologic cells of the leukemia, the cultured well differentiated adenocarcinoma cells and endotoxin. (1) The lysates of the pathologic cells of the leukemia and the cultured cells showed prekallikrein activation. Endotoxin showed prekallikrein activation via factor XII. (2) Serine proteases (factor Xa, thrombin,
plasmin
and trypsin) activated prekallikrein in the plasma and the purified prekallikrein. (3) Antithrombin III, aprotinin and FOY inhibited prekallikrein activation. Antithrombin III was promoted by heparin in its inhibitory effect.
...
PMID:Changes of prekallikrein in the cases with disseminated intravascular coagulation syndrome. 16 Jan 91
The fibrinogen and fibrin degradation products (FDP) in serum samples taken from nine patients with suspected
disseminated intravascular coagulation
have been characterized using a method of immunoprecipitation followed by sodium dodecyl sulphate polyacrylamide gel electrophoresis. Aall of the serum samples contained a fragment with the same electrophoretic mobility as fibrinogen fragment X, while the majority also had evidence of fragments with similar mobility to fibrinogen fragments Y and D. In eight of the nine serum samples there was strong evidence of the D-dimer fragment that is released by
plasmin
lysis of crosslinked fibrin. Also present in all but one of the samples were fragments of higher molecular weight than fibrinogen which were probably soluble, non-clottable, factor XIIIa induced crosslinked derivatives of fibrinogen. These results suggest that during
disseminated intravascular coagulation
thrombin and activated factor XIII act upon fibrin(ogen) to form complexes that are subsequently lysed by
plasmin
to produce soluble crosslinked derivatives of fibrin.
...
PMID:Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation. 36 18
Masugi nephritis was induced in dogs in which platelet count, fibrinogen, antithrombin activity, plasma prekallikrein and immediate
plasmin
inhibitors were coincidentally decreased immediately after the injection of nephrotoxin serum. It was found that the grade of decrease of urinary kallikrein excretion following these immediate reactions were parallel with the grade of renal damages. By the pretreatment with heparin or the
defibrination
with snake venom, however, the histological findings of Masugi nephritis showed rather severe damage. Based on the consumption of coagulation factors, kallikrein, kinin and their inhibitors in the development of this nephritis, it was postulated that inauguration of coagulation and activation of kallikrein contributed to the development of glomerulonephritis. The treatment or prevention of this coagulation process with heparin or snake venom, however, gave untoward effects on the pathological process in this experiment.
...
PMID:Participation of kallikrein, coagulation/fibrinolysis parameters in the development of glomerulonephritis. 49 36
Fibrinogen-fibrin-related antigen (FR antigen) was isolated from as little as 1 ml of human plasma by immuno-affinity chromatography with agarose-bound antibody to human fibrinogen. N-terminal analysis was performed to determine the nature and extent of proteolytic degradation of the FR antigen in patients with
disseminated intravascular coagulation
and in normal subjects. Thrombin cleavage of the A- and B-peptides from fibrinogen in vitro was monitored by the appearance of N-terminal glycine, and an increase in glycine was shown in the FR antigen of patients with
disseminated intravascular coagulation
. As
plasmin
progressively degraded fibrinogen, increases in N-terminal alanine, aspartic acid and lysine were observed, corresponding to the known
plasmin
-cleavage points of fibrinogen; increases in these N-terminal amino acids were also found in the patients' FR antigen. Thrombin treatment in vitro was used to remove fibrinopeptide A (N-terminal alanine) from the samples and to reflect specifically the N-terminal alanine at the
plasmin
-cleavage point (Arg-42-Ala-43) of the B beta-chain on assay; this alanine was increased progressively in the FR antigen of a patient during urokinase therapy, and was high in other patients when the FR antigen was examined by this procedure.
...
PMID:Quantitative N-terminal analysis of fibrinogen-fibrin-related antigen [FR antigen] from human plasma. 54 36
We have examined the consequence of infusions into rabbits of the products of limited
plasmin
hydrolysis of fibrin (early fibrin degradation products, or early fdp) containing defined quantities of fibrin fragment X. For comparison, early fibrinogen degradation products (early FDP) and late fibrin degradation products (late fdp) consisting almost exclusively of core fragments D and E were infused into separate groups of animals. Components of early fdp, probably fibrin fragment X, behaved in many respects like fibrin monomer. Infused unlabeled early fdp produced circulating soluble fibrin complexes with 125I-labeled fibrinogen. 125I-labeled early fdp rapidly accumulated in the spleen and liver and also to a significant degree in the lungs as insoluble, nonextractable tissue-bound protein; in contrast, only minimal quantities of early FDP and late fdp accumulated in organs. When 125I-labeled early fdp were administered to animals given continuous infusions of epsilon-aminocaproic acid to block fibrinolysis, substantial amounts of radioisotope also accumulated in the kidneys. These observations suggest a possible pathophysiological role for the products of lysing fibrin encountered in clinical states associated with
disseminated intravascular coagulation
.
...
PMID:Biological behavior of higher molecular weight products of fibrinolysis. 87 68
1
2
3
4
5
6
7
8
9
10
Next >>